Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2016

View Archived Issues

Sumitomo Dainippon Pharma recaps clinical developments of first quarter of fiscal 2016

Ligand Pharmaceuticals licenses three programs from Nucorion Pharmaceuticals

The Vanderbilt University reports mGlu4 receptor PAMs

Bayer Healthcare patents chemokine receptor antagonists

Korea Research Institute of Bioscience and Biotechnology discloses antibiotic compounds

Janssen Pharmaceutica introduces cannabinoid CB1 inverse agonists

University of California, Oakland describes heat schock protein inhibitors

Atovaquone alleviates tumor hypoxia and increases the sensitivity of tumor cells to radiation

Nusinersen meets primary endpoint at interim analysis of phase III ENDEAR study

Hetlioz becomes available in Germany

Biogen initiates phase I trial of BIIB-068 in healthy subjects

Celgene reflects on key events of second quarter 2016

Orexigen Therapeutics completes acquisition of U.S. rights to Contrave

NP-03 shows promise for AD in vivo

FDA grants breakthrough therapy designation to MEI Pharma's pracinostat

Tetraphase Pharmaceuticals begins dosing patients in phase I study of TP-6076

SciFluor Life Sciences to begin clinical testing of SF-0166 for retinal diseases

Genetic variant in BMAL1 is associated with higher risk of CVD

Cognitive tests are potentially useful to test new AD therapy efficacy

Aptevo Therapeutics launches after separation from Emergent BioSolutions

Heron Therapeutics reports results from two phase II studies of HTX-011

Phase III ALCANZA trial of Adcetris in CTCL meets primary endpoint

FDA grants fast track status to Vaccinex's VX-15 for Huntington's disease

Scynexis' SCY-078 shows favorable safety, tolerability in phase II study in invasive candidiasis

Ebola vaccine demonstrates complete protection in nonhuman primate challenge models

EC grants orphan drug designation to C21 for the treatment of IPF

National Parkinson Foundation and the Parkinson's Disease Foundation complete merger

InBios receives development support to advance Zika diagnostic

Pfizer acquires Bamboo Therapeutics and significantly expands its gene therapy expertise

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...